FUNDAMENTALS |
MarketCap: |
12 599 mill
|
EPS: |
-11.74
|
P/E: |
-28.09
|
Earnings Date: |
May 02, 2024 |
SharesOutstanding: |
38.20 mill
|
Avg Daily Volume: |
0.972 mill
|
RATING
2024-03-15 |
B
|
Neutral
|
RATINGS |
Rating CashFlow: |
Neutral
|
|
Return On Equity: |
Sell
|
|
Return On Asset: |
Neutral
|
|
DE: |
Sell
|
|
P/E: |
Strong Sell
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | | | | | n/a | n/a |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -28.09 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-4.78x
|
Company: PE -28.09 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
$4.56
(-98.62%)
$-325.27
|
Date: 2024-03-20
|
Expected Trading Range (DAY) |
$ 325.80 - 333.86
( +/- 1.22%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-03-18 | Wheadon David E. | Sell | 990 | Common Stock |
2024-03-18 | Wheadon David E. | Sell | 25 000 | Option (right to buy) |
2024-03-18 | Wheadon David E. | Sell | 8 500 | Option (right to buy) |
2024-03-18 | Wheadon David E. | Sell | 5 000 | Option (right to buy) |
2024-03-18 | Wheadon David E. | Sell | 1 904 | Option (right to buy) |
INSIDER POWER |
-93.83
|
Last
100 transactions |
Buy:
115 486 | Sell:
3 548 924 |
Forecast:
01:40 - $362.99
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$329.83 (0.03% )
|
Volume |
1.283 mill
|
Avg. Vol. |
0.972 mill
|
% of Avg. Vol |
132.02 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For KRTX
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:34 | sell | $316.15 | N/A | Active |
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.